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Abst rac t
Atopic dermatitis is a chronic and recurrent inflammatory dermatosis with concomitant intensive pruritus, and is 
diagnosed both in children and adults. Atopic dermatitis-patients are predisposed to have bacterial, viral and fungal 
skin infections; they also suffer from an increased risk of developing food allergies (especially, at an infantile age), 
allergic rhinitis, or bronchial asthma (a so-called atopic march). Currently, an increasing atopic dermatitis incidence 
constitutes a serious medical problem that regards not only dermatology and allergology, but also paediatrics, and 
family medicine. The basis for atopic dermatitis treatment and prophylaxis is restoration of epidermal barrier func-
tions by means of tailored emollients. Atopic dermatitis therapies should effectively eliminate clinical symptoms of 
the disease, prevent exacerbations as well as complications, and improve patients’ quality of life.
Key words: atopic dermatitis, allergic march, elimination diet, emollients, topical glucocorticoids, topical calcineurin 
inhibitors, proactive therapy, wet dressings therapy, wet dressings.
The article was published in the journal "Dermatology Review/Przegląd Dermatologiczny" 2019, 106, 354–371,
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Introduction
Atopic dermatitis
Atopic dermatitis (AD) is a common chronic recurrent 
non-infectious inflammatory disease that most often 
appears in early childhood and may persist for life. The 
disease is characterized by periods or exacerbations and 
remissions. The main symptoms include: intense pruri-
tus and skin dryness, erythematous inflammatory skin 
lesions with eczematous morphology; chronic phase of 
the disease involves thickening (lichenization) and ex-
foliation of the epidermis. Patients tend to suffer from 
recurrent bacterial, viral and fungal skin infections. The 
lesions are most often form on the bends of elbows and 
knees, on the face and neck, but they may also cover 
the skin of the entire body (erythroderma). The site of 
exanthemata is age-related. Atopic dermatitis is a result 
of complex genetic, epigenetic, environmental and im-
munological interactions with a concomitant epidermal 
barrier defect [1, 2].
During the first years of life, AD incidence is similar 
in both sexes; after the age of 6, prevalence of the fe-
male sex over male is noted (3 : 2) [3, 4]. Atopic dermati-
tis usually starts in early childhood. It is believed that in 
45% of infants symptoms appear before the 6th month 
of life, and in 50% before they are 1 y/o. In 40–80% of 
children the disease tends to recede before the age of 
5, and in 20% of patients it is present till adulthood. In 
one out of four adult AD-patients, the disease develops 
de novo [5, 6]. Large cities in Poland have been experi-
encing an increase in AD incidence. The AD incidence 
percentage among children ranges from 4.7 to 9.2%, 
and among adults from 0.9% to 1.4% [7].
Chronic course of the disease and continual pruritus 
significantly decrease the quality of life of patients and 
their families, and lead to serious socio-economic con-
sequences. Sleep disorders, absence at school and work, 
and social isolation may be the reasons behind depres-
sion, and even suicidal thoughts.
Allergic march
Atopic dermatitis may be concomitant with other 
IgE-dependent atopic diseases: bronchial asthma, al-
lergic upper respiratory congestion and catarrhal con-
junctivitis, and sometimes even food allergies. Epide-
miological studies and clinical observations indicate 
the existence of a specific sequence of occurrence of 
atopic diseases. This phenomenon was called an allergic 
march and does not always have a classic course. About 
34% of AD-patients develop allergic rhinitis, 20–35% – 
asthma, and 15% – clinical symptoms of food allergies. 
Genetic factors and external factors such as stress, eat-
ing habits, infections, cigarette smoke, or smog, mainly 
predispose individuals to develop an allergic disease 
and allergic march [1, 2].
Treatment – general recommendations
An increase in AD incidence constitutes a serious 
medical and therapeutic problem that regards not only 
dermatology and allergology, but also paediatrics and 
family medicine [1, 2, 8–10]. While commencing the AD 
treatment, not only should patient’s age and site of skin 
lesions be taken into account, but also intensity of the 
inflammation (Table 1), and concomitant diseases, includ-
ing: infections, contact allergy, food allergy, eye diseases, 
mental diseases, obesity, and cardiovascular diseases [8–
10]. Contact eczema is confirmed in about 50% of children 
with initial diagnosis of AD [11, 12].
Special scales are used to objectively measure the in-
tensity of skin lesions in AD [13]. SCORAD (Scoring Atopic 
Dermatitis) has been recognized to be the most reliable 
tool to measure clinical symptoms of AD – together with 
EASI (Eczema Area and Severity Index) [13, 14]. SCORAD 
allows for assessing the area of involved skin, and the 
intensity of particular skin symptoms (dryness, erythe-
ma, oedema, effusion, erosions, lichenization) on a point 
scale from 0 to 3. Moreover, SCORAD includes the assess-
ment of subjective symptoms: sleep disorders and pruri-
tus intensity from 0 to 10; the assessment is provided by 
the patient. It is available for physicians as a computer 
or smartphone application. The scale facilitates treat-
ment monitoring and objectivizing treatment results. The 
PO-SCORAD (Patient-Oriented Scoring Atopic Dermatitis) 
version based on SCORAD was created for patients. It 
correlates well with SCORAD, and correlates better with 
other scales that assess quality of life (e.g. DLQI) [13, 15]. 
It is available as a convenient computer or smartphone 
application (https://www.poscorad.com/#/poscorad/
pl). The application allows patients to assess the inten-
sity of the disease themselves, and track its intensity; it 
also reminds the patients to use emollients, and sends 
information to physicians during the period between ap-
pointments. By introducing elements of self-assessment, 
treatments are more effective and less costly, while pa-
tients’ quality of life is improving [16].
EASI scale allows for assessing intensity of lesions 
from 0 to 3. The scale does not include subjective symp-
toms. It is mainly used in clinical studies. Other, less 
common scales that assess intensity of lesions in AD are 
POEM (Patient-Oriented Eczema Measure) and IGA (In-
vestigators’ Global Assessment) [15].
The basis for AD treatment is a combination of ev-
eryday emollient therapy that restores epidermal barrier 
functions and anti-inflammatory treatment with simulta-
neous avoidance of contact with allergens and irritating 
factors (Tables 1 and 2). During periods of disease exac-
erbations, possible concomitant bacterial, viral or fungal 
infections should be taken into account, and proper anti-
microbial treatment should be applied. If the topical ther-
apy fails to bring improvements, it is recommended to 
commence phototherapy or systemic treatment [17–19].
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Primary therapy
Education
Lack of co-operation from the patient’s side and/or 
caretaker’s is a common reason behind therapy’s fail-
ure, and thus, educational programs, “schools of atopy”, 
informational leaflets, films, etc. are necessary and sig-
nificant parts of the treatment. The patient and/or their 
caretaker should actively participate in the treatment 
process and have sufficient amount of information re-
garding the disease. When patients understand the ne-
cessity of continual long-term and often multi-specialist 
treatment, the efficacy is much improved [20–30].
Prophylaxis
Primary prophylaxis – regards children in the risk 
group that do not have any disease symptoms. Its aim is 
to prevent the disease development. Activities associated 
with primary prophylaxis include prolonged breastfeed-
ing, refraining from smoking during pregnancy, limiting 
exposure to airborne allergens, mainly dust mites, and 
application of emollients from the first day of life. Both 
in children with population risk and in high-risk groups, 
it is recommended to breastfeed exclusively until the 4– 
6 month of life. Breastfeeding allows for limiting the ad-
verse reactions to protein from other species. Moreover, 
human milk satisfies all nutritional needs, it is a natu-
ral and the most balanced food; it contains a number of 
biologically active substances with immunological value, 
among others.
Secondary prophylaxis – regards patients, in whom 
early symptoms of the disease were confirmed. Its aim is 
to prevent the appearance or exacerbation of symptoms. 
Emollient therapy (every 4–6 h), avoidance of irritating 
factors and stress, as well as elimination of allergens 
responsible for the symptom appearance are recom-
mended. An important part of this prophylaxis types is 
vocational guidance service.
Tertiary prophylaxis – recommended in patients with 
full-blown AD in order to decrease the intensity of symp-
toms and frequency of their recurrence, and to prevent 
the development of concomitant diseases. This type of 
prophylaxis includes psychological counselling, and edu-
cation of patients in order to teach them how to control 
the symptoms and live with the disease [31].
While taking patient’s history, factors that potential-
ly intensify the clinical symptoms should be looked for. 
Most frequently these include: exposure to airborne and 
contact allergens, food, various environmental irritating 
factors (including cigarette smoke and microorganisms), 
climate factors, stress, and disorders of the hormonal 
balance [17, 18, 32]. Not every AD-patient reacts to all of 
Table 1. Atopic dermatitis (AD) therapy depending on the 
intensity of the disease according to SCORAD [17–19] (the 
next steps in the table complement previous treatment)
Severe AD
SCORAD > 50
Hospitalization
Cyclosporine A (CyA) 
Dupilumab
Methotrexate (MTX), mycophenolate mofetil 
(MMF)
Azathioprine (AZA)
Oral GCs (maximum for 7 days)
Moderate AD
SCORAD 
25–50
Wet dressings
Climate therapy
Psychological/psychiatric interventions
Phototherapy: UVB 311, UVA 1, PUVA (adults)
Proactive therapy
Mild AD
SCORAD < 25
Antiseptics
Topical calcineurin inhibitors
Topical glucocorticosteroids (topical GCs)
Primary 
therapy
Emollient therap
Avoid clinically significant allergens
EDUCATION
Table 2. Primary AD therapy
Emollient 
therapy
Direct application of emollients on the 
inflammation is tolerated badly
It is best to use anti-inflammatory drugs 
(topical GCs, topical calcineurin inhibitors)
Apply at least 2–3 times a day!
Glycerol is better tolerated than urea and 
sodium chloride
Propylene glycol causes irritation easily and 
should not be used
It is recommended to use emollients without 
protein allergens and haptens 
Skin cleaning Gently and thoroughly; mechanically
Cleaning substances with/without aseptic 
substances
Proper galenic forms
Physiological pH within the 5.5–6 range
Fast baths ≤ 5 min, temp. 27–30°C
Adding to the bath 1/2 glass of sodium 
hypochlorite eliminates pruritus
Education Apply proper amounts of emollients  
(250–500 g/week)
Explain/demonstrate how to use them
When using different topical drugs, keep 
a time gap
At least once a year remind about the 
recommendations!
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the abovementioned factors. Hypersensitivity to airborne 
allergens regards most often older children and youths 
as well as adults [33]. Prophylaxis includes avoidance of 
clinically significant allergens for a given patients, i.e. pol-
len (from trees, shrubs, grasses, weeds, grains) during 
pollination time, allergens associated with dust mites, 
and contact allergens in case of positive test results and 
their connection to clinical symptoms [18]. Room ventila-
tion and spending less time in closed spaces are impor-
tant parts of the therapy.
Elimination diet
Elimination diet in recommended in patients to de-
termine the etiopathogenetic connections between food 
intolerance and AD (Table 3) [34]. Eliminating harmful food 
from patient’s diet together with proper pharmacological 
treatment successfully helps to achieve satisfactory clini-
cal improvements and accelerate the treatment process 
[33, 35–38]. Individual recommendations with regard to 
eliminating chosen food from the diet regard only those 
patients, in whom a negative influence of food intolerance 
on clinical course of the primary disease was confirmed in 
an objective way [35].
 Elimination diet in AD-patients with concomitant 
hypersensitivity to food intolerance
Food that contains harmful allergens needs to be 
temporarily eliminated from the diet of an AD-patient, 
and substituted with other non-allergic components 
with balanced or similar nutritional characteristics [39]. 
The elimination usually involves one or two nutritionally 
bivalent foods (most often: cow milk and milk products, 
eggs, soya, crop plants, fish, and some fruit as well as 
vegetables).
Validity criteria of the elimination diet are deter-
mined by: confirmed concomitant food intolerance 
and therapeutic efficacy of the diet (remission of skin 
symptoms or their total remission, minimization of ex-
acerbation and recurrence episodes). Due to the lack of 
guidelines as to the duration of elimination of harmful 
food from the diet, the duration needs to be set indi-
vidually for every patient. When the elimination diet 
needs to be used long-term, at least once a year a chal-
lenge test with the harmful food should be performed 
on the patient. The test aims at assessing the activity of 
the food intolerance process. A systematic decrease in 
this activity is a sign of an AD-patient acquiring immuno-
logical tolerance. The process, colloquially called “grow-
ing out of a food allergy”, results from the used dietetic 
and pharmacological treatment [39].
In case of severe AD involving a multifood/polyvalent 
allergy, it may be necessary to eliminate even a couple of 
foods simultaneously from the sick child’s diet. Elimina-
tion diet recommended to such patients should be bal-
anced, what is of key importance especially for patients 
at the developmental age [39, 40].
Patients with multifood allergies
Patients with multifood allergies that are hypersen-
sitive to both cow milk proteins and milk substitute 
products and some other products than milk constitute 
a special subgroup of AD-patients. Such patients are in-
troduced to basic formulas that substitute milk in order 
to balance their diet. They are totally non-allergic to the 
patient’s organism since native protein fraction of cow 
mild has been substituted with a pool of synthetic amino 
acids [41].
In case of an infant with AD characterized by mod-
erate-severe and severe course that is fed naturally and 
in whom appearance of skin lesions has a confirmed 
causal relation to mother’s eating habits, there are in-
dications for temporary elimination of some foods from 
her diet. In most cases the elimination regards milk and 
milk products, eggs, earthnuts, nuts, some fruit and veg-
etables. Composition of the mother’s elimination diet 
and its duration should be supervised by a physician or 
dietician. It should be remembered that the menu of the 
breastfeeding mother who uses elimination diet should 
be enriched with 500 kcal/day, include a substitute of 
another protein than the one eliminated from the diet, 
and supplemented with necessary intake of mineral salts 
(including 1 g Ca++/day) and vitamins [41].
If a breastfeeding mother is on elimination diet 
an the condition of her infant fails to improve within 
2 weeks, further food elimination needs to be discontinued.
If an infant who is breastfed experiences an anaphy-
lactic reaction that is associated with its mother eating 
food that allergizes the infant (e.g. milk, eggs, fish, earth-
nuts), it is an indication to discontinue breastfeeding im-
mediately and give the infant a formula that substitutes 
milk. Such formulas contain hydrolysed casein fraction or 
whey protein, and have a decreased ability to allergize as 
compared with native protein fractions of cow milk [41].
Emollient therapy
Prophylactic activities include also emollient therapy 
as it has been confirmed that using it since the birth of 
Table 3. Diagnostics of food allergies in patients with 
moderate or severe AD, in whom symptoms persist 
despite general treatment and topical therapies [35, 38]
Age Tests
< 5 y/o Cow milk, eggs, wheat, soya, and peanuts
> 5 y/o Choosing food for tests should be done 
according to the patient’s history and 
most common allergies in this population: 
nuts, shellfish, fish
Youths, older age 
groups
Concomitant pollen and food allergy 
should be taken into account: apples, 
celeries, carrots, hazelnuts
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a child that belongs to an AD risk group significantly de-
creases the risk of developing AD. Emollients applied from 
the first day of life in children born in atopic families de-
crease the risk of developing AD by half [42–44]. A role of 
emollients in inhibiting the development of allergic march 
and their common application in prophylaxis for AD group 
risks and general population is being examined [44–48].
Emollients contain occlusive substances (petroleum 
jelly, paraffin, mineral oils) that decrease transepidermal 
water loss (TEWL), moisturizing substances – water-
binding humectants (e.g. urea, sorbitol, glyceryl alcohol, 
lactic acid), and lipids that seal the epidermal barrier (ce-
ramides, cholesterol, polyenic acids) [49, 50]. Emollients 
reduce clinical symptoms of AD in children and adults, 
while preventing exacerbations and recurrence of atopic 
eczema, maintain remission state after its induction 
with topical anti-inflammatory preparations, and visibly 
decreasing the amount of used topical GCs (steroid spar-
ing effects) [51–62].
It is recommended to use emollients 2–3 times a day 
in the amount of minimum 200 g/week in small children 
and 500 g/week in adults [18, 26]. They should be chosen 
individually depending on the level of skin dryness, activ-
ity during the day and night, and a possible contact aller-
gy. Since some emollients contain ingredients with a vari-
able allergizing potential, it is necessary to read about 
their composition before use [63]. Applied emollients 
should not contain heptens that cause contact allergies 
(odoriferous substances, including essential oils, preser-
vatives such as methylisothiazolinone, and lanoline/wool 
alcohol), and potentially allergizing proteins, especially in 
the group of patients who are under the age of 2 [18]. The 
risk for developing a secondary contact allergy to skin 
care products and drugs used externally in AD treatment 
is the highest in severe cases of this disease [64]. It is not 
recommended to use pure oil, e.g. coconut, as it dries the 
skin and intensified TEWL. Propylene glycol should not 
be used in children under 2, because it can easily irritate 
gentle epidermis of a child [18]. Due to the fact the urea 
may cause skin irritation or burning sensation, its con-
centration in emollients for children and youths should 
be lower than in preparations used by adults [65].
Currently, it is recommended to use emollients plus 
enriched with additional active substances such as fla-
vonoids, saponins, or bacterial lysates with Aquaphilus 
dolomiae, Vitreoscilla filiformis. They show anti-inflam-
matory effects by inhibiting cytokines (TSLP, IL-18, IL-2, 
IL-12, IL-17, IFN-g, IL-1b, TNF-a, IL-4) and chemokines 
(MCP3/CCL7, MDC/CCL22, MIP-3a/CCL20) [18, 38], anti-
pruritic effects [66], they support congenital immunity 
by activating TLR2, TLR4, TLR5, and natural anti-bacterial 
peptides (hBD-2, cathelicidin LL-37, psoriasin) [67], inhibit 
the growth of Staphylococcus aureus, and do not disturb 
the composition of bacterial flora; they also restore ho-
meostasis of skin microbiome in AD [68, 69], and recon-
struct the epidermal barrier. 
Opened emollient containers need to be stored at 
refrigerators; it is recommended to use containers with 
pumps or a lid that ensures sterility, to avoid direct ap-
plication of the preparation with hands, and not to share 
the ointment with others as the risk of contamination 
with microorganisms increases [18, 19].
Atopic skin requires special care processes (Table 3). 
Short baths with the use of preparations substituting 
soap and emollient therapy immediately after the bath 
(within 3 min) are recommended [18, 19].
In case of inflammation, topical anti-inflammatory 
therapy should be applied first, as even the best emol-
lients may irritate the inflamed skin, and discourage the 
patients from their further use [18].
Topical anti-inflammatory therapy
Topical glucocorticosteroids
Topical glucocorticosteroids (topical GCs) have con-
stituted the basis for AD treatment for over 50 years. 
Together with emollients they ensure excellent thera-
peutic effects. Due to skin dryness, topical GCs in the 
form of ointment are preferred, except for oozing le-
sions – in the case of these lighter forms should be 
applied (lotion, aerosol, cream). Application of topi-
cal GCs decreases skin colonization with S. aureus. 
During exacerbation periods, it is recommended to use 
topical GCs with a moderate effect in the evening, be-
cause they also have anti-pruritic qualities apart from 
providing anti-inflammatory effects [17–19].
Due to high efficacy obtained within a short time since 
the therapy introduction and low price, topical GCs are often 
abused. In children, these drugs should be used carefully and 
under close dermatological supervision, because children 
have a different skin structure. The choice of a preparation 
should be associated with disease intensity, site of lesions, 
age of the patients, medium in which the active substance 
is suspended, and drug registration (Table 4). According to 
the Summary Product Characteristics (SPC), fluticasone pro-
pionate, alclometasone, and betamethasone valerate are 
allowed for patients above the age of 1, whereas hydrocor-
tisone butyrate, mometasone furoate, and methylpredniso-
lone aceponate are allowed for patients above the age of 2. 
Other topical GCs may be used above the age of 6 or 12.
Table 4. Age of use topical GCs according to the SPC
Topical GCs Age from the SPC
Fluticasone propionate > 1 y/o
Alclometasone 
Betamethasone valerate
Hydrocortisone butyrate > 2 y/o
Mometasone furoate
Methylprednisolone aceponate
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 Adverse reactions of preparations containing 
topical glucocorticosteroids
Long-term use of topical GCs, especially from the 
groups that have potent effects, is often associated with 
adverse reactions such as: skin atrophy, permanent vaso-
dilation (telangiectasias), stretch marks, hypertrichosis, 
dyspigmentation, perioral dermatitis, bacterial and/or 
fungal superinfections, cataracts, glaucoma, withdrawal 
effect (exacerbation of skin lesions after drug discon-
tinuation), and tachyphylaxis (gradual decrease in drug 
efficacy as the drug is used long-term). Paradoxically, 
a contact allergy may also develop. Topical application 
of potent topical GCs on large areas in children, and in-
fants in particular, may cause general adverse reactions: 
inhibition of the hypothalamic-pituitary-adrenal axis, 
growth failure, and osteoporosis. Fear of adverse reac-
tions is the most common reason for non-observance of 
physician’s recommendation by patients, and in case of 
children – by their parents, what in turn leads to lack 
of treatment efficacy. To avoid potential adverse reac-
tions, it is recommended to use a so-called intermittent 
therapy that is based on using topical GCs only 2–3 days 
a week and emollients alternately. Topical GCs should be 
used according to the manufacturer’s recommendations, 
because its frequent use does not increase the treatment 
efficacy – it rather increases the risk for adverse reac-
tions. Additionally, a FTU (finger tip unit) rule may help in 
safe application of these drugs [17, 70–73].
Steroid phobia
More than half of AD-patients fear the use of topi-
cal GCs, what has been revealed by studies conducted 
among the patients. Furthermore, it was showed that 
patients have little knowledge about the therapeutic po-
tential of topical GCs and their adverse reactions, and the 
main source of knowledge for patients is the Internet. The 
problem of steroid phobia is not limited to Poland, but re-
gards the entire Europe and is a reason behind inefficacy 
of topical AD therapies. Proper education of patients and 
interpersonal relations between patients and physicians 
that are based on mutual trust, could improve the efficacy 
of AD treatment [74]. Patients with steroid phobia should 
be identified and educated by physicians and pharmacists, 
what might improve observance of recommendations [18].
Topical calcineurin inhibitors
Topical calcineurin inhibitors – tacrolimus and 
pimecrolimus – inhibit activation of T lymphocytes and 
release of inflammatory cytokines. Pimecrolimus as a 1% 
cream is recommended as the first-line treatment in mild 
AD, and its clinical profile suggested that it may be also 
considered as a treatment of choice in mild and mod-
erate AD, both in children and adults, especially within 
sensitive skin regions [75]. Tacrolimus as 0.03% and 
0.1% ointment is recommended in moderate and severe 
atopic eczema. Tacrolimus, as compared with pimecroli-
mus, shows faster and more potent effects, and clinical 
improvements after its use are visible already during the 
first week of treatment. These preparations are applied 
twice a day till inflammation disappears, with special in-
dication for sensitive skin regions such as bends, face, 
neck, intertriginous areas, and the skin of genital organs 
both in adults and children. Patients treated with topi-
cal calcineurin inhibitors should have effective sun pro-
tection recommended [18]. As opposed to topical GCs, 
topical calcineurin inhibitors do not inhibit collagen syn-
thesis, do not cause epidermal thinning, vasodilation, 
and do not damage the skin barrier. The cause neither 
cataracts nor glaucoma [18]. The most common adverse 
reaction associated with the use of topical calcineurin in-
hibitors is connected to neuropeptide release – a burning 
sensations and skin reddening that usually lasts about 
30 min at the site of application and disappears after sev-
eral days [17, 18, 75, 76].
Based on existing analyses of treatment results, it is 
believed that limits regarding the use of pimecrolimus 
in infants are unfounded. It is suggested to prepare new 
recommendations and warning on labels of topical calci-
neurin inhibitors [77]. Tacrolimus as a 0.1% ointment has 
a more potent effect than pimecrolimus as a cream. Topi-
cal calcineurin inhibitors show a significant therapeutic 
effect in long- and short-term treatment of AD [18].
Treatment of acute inflammatory lesions should in-
clude topical GCs initially, and then topical calcineurin 
inhibitors [18]. Topical GCs are also recommended to 
control pruritus at an initial stage of AD exacerbation; 
then, until the symptoms disappear – topical calcineurin 
inhibitors [19]. Polidocanol may be used topically in order 
to decrease pruritus; furthermore, UVB and UVA1 photo-
therapy is recommended [18, 19].
Proactive therapy
A proactive therapy is a long-term intermittent 
therapy involving topical anti-inflammatory prepara-
tions used at sites where eczema used to appear, after 
its remission. Studies involving tacrolimus in proactive 
therapies lasted up to 12 months. A decrease in fre-
quency of AD exacerbations, extension of the period till 
the first disease exacerbation, improvement in patients’ 
quality of life, and decrease in AD treatment costs were 
showed among patients that used proactive therapies 
with tacrolimus. A proactive therapy used twice a week 
for a longer period of time may help reduce disease re-
currences [18, 78, 79].
Wet dressings
A so-called “wet dressings” therapy may be used in 
children aged from 6 months to 10 years with severe AD 
(SCORAD above 50 points). This method uses two lay-
ers of dressings: the first wet one is placed directly on 
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the skin with applied emollient or 0.05% fluticasone pro-
pionate or mometasone furoate that is properly diluted 
(1 : 3, 1 : 9, 1 : 19), and then the second dry layer of a su-
perficial dressing. The therapy lasts from 3 to 14 days 
and is conducted under strict supervision of a physician, 
with the use of diluted topical GCs, most often in the 
hospital, and requires monitoring of the cortisol level in 
the mornings, because its adverse reaction may include 
suppression of adrenal glands [80].
Wet dressings have a cooling, anti-inflammatory, 
and anti-pruritic effects. They create a mechanical bar-
rier against external environmental factors and protect 
the child from scratching, while potentially decrease the 
amount of used topical GCs. On the other hand, they 
cause an increased absorption of topical GCs, risk for 
developing bacterial infections, and skin atrophy. More-
over, this form of therapy requires training of caretakers 
or patients, what increases its cost [81].
Treatment by means of “wet dressings” is a safe ther-
apy in severe and recurrent AD cases; it is tolerated well 
by children and significantly increases their quality of life 
[82]. Spectacular effects observed already after a week 
of treatment with this method are highlighted, however, 
in some cases within 4 weeks from the treatment dis-
continuation a considerable worsening of AD may occur; 
hence, studies on proactive application of wet dressings 
are conducted [82]. Studies’ results encourage to use this 
method, however, further controlled standardized clinical 
studies are need to recommend it [83].
Antimicrobial treatment
Skin of AD-patients does not have a natural mi-
crobiological diversity [84, 85]. During disease exac-
erbation periods, bacterial flora of AD-patients’ skin 
is dominated by S. aureus [85]. Every exacerbation 
of AD symptoms may be associated with an infec-
tion, most often staphylococcal, and eradication of 
S. aureus improves the disease course [86]. Studies 
indicate therapeutic efficacy of octenidine, chlorhexi-
dine, mupirocin, fusidic acid, and retapamulin against 
S. aureus. Usage of antiseptic baths with addition of 
sodium hypochlorite decreases the number of bacteria, 
reduces pruritus, and improves patient’s clinical condi-
tion [18]. It is not recommended to use topical antibiotics 
chronically as resistance to antibiotics may develop [18, 
19, 86–89]. A justification for the use of oral antibiotics is 
exacerbation of AD with clinical signs of bacterial infec-
tion. In other cases, treatment involving oral antibiotics 
is not recommended [17–19, 90, 91]. Short cycles of oral 
antibiotics, e.g. cephalosporin, may be considered in pa-
tients with clinical signs of an infection with S. aureus 
[18, 19]. Due to a disordered profile of antibacterial pep-
tides in AD, achieving a continual skin decolonization is 
practically impossible [88]. Anti-inflammatory treatment 
(topical calcineurin inhibitors, topical GCs, UV) decrease 
colonization with S. aureus in AD [17].
Atopic skin infection with herpes simplex virus (HSV) 
often manifests itself as eczema herpeticum (Kaposi 
varicelliform eruption; eczema herpetiformis – EH) and 
requires immediate systemic antiviral treatment with 
acyclovir [18, 92]. AD-patients with lesions found on the 
head, face, and neck, also suffer from concomitant infec-
tion with yeasts – Malassezia sp., which disappears after 
the use of topical antifungal treatment (ketoconazole or 
ciclopirox olamine) [18, 93–95].
Phototherapy
Phototherapy may be used as monotherapy or in 
combination with topical GCs (Table 5). Narrow-band 
UVB (NB-UVB – 311 nm) is an effective and safe method 
in the treatment of moderate and severe AD in school 
children and adults [96]. Furthermore, moderate doses 
of UVA1 (340–400 nm) are recommended for adults with 
AD; PUVA may be used in selected cases [18, 19, 97, 98]. 
A limitation of phototherapy is its little availability. Rare 
adverse reactions include: erythema and tenderness after 
radiation, pruritus, burns and post-sun skin damage, skin 
cancers, melanoma, lentigines, photosensitivity reactions 
(mainly polymorphous light eruptions), folliculitis, photo-
onycholysis, HSV reactivation, excessive facial hair growth, 
and cataracts [97].
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Table 5. Phototherapy in AD [96, 97]
Narrow-band UVB 
(NB-UVB) 
Initiating dose for phototype I: 130 mJ/cm2, II: 220 mJ/cm2, III: 260 mJ/cm2, IV: 330 mJ/cm2, V: 350 mJ/cm2, 
VI: 400 mJ/cm2. With every radiation the dose is increased for phototype I with 15 mJ/cm2 (max. dose 
2000 mJ/cm2), II – with 25 mJ/cm2 (max. dose 2000 mJ/cm2), III – with 40 mJ/cm2 (max. dose 3000 mJ/cm2), 
IV – with 45 mJ/cm2 (max. dose 3000 mJ/cm2), V – with 60 mJ/cm2 (max. dose 5000 mJ/cm2), VI – with  
65 mJ/cm2 (max. dose 3000 mJ/cm2). Subsequent doses 3–5 times. In case 1 week of radiation is missed –  
the last dose may be maintained; 2 weeks – decrease the dose by 25%; 3 weeks – decrease the dose by 
50%; 4 weeks – start from the beginning
Adjuvant therapy  
NB-UVB method
Disappearance of lesions > 95%: last dose once/week for 4 weeks, then 1 dose decreased by 25% every 
2 weeks – for 4 weeks, then once/month 50% of the highest dose
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